A Food and Drug Administration (FDA) advisory panel overwhelmingly rejected MDMA-assisted therapy for treating post-traumatic ...

Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

The FDA rejected an application to approve MDMA, also known as ecstasy, as a treatment for PTSD. Next up among the ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for ...

Advocates are pushing for approval of psychedelic-assisted therapy from the FDA, seeking a means of therapy without fear of ...

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

Efforts to make MDMA legally available as a psychotherapeutic catalyst hit a daunting roadblock in August. The Food and Drug ...

The CEO's departure comes after Lykos co-founder and longtime psychedelic medicines advocate Rick Doblin stood down from the ...

Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy.

Delve into the psychedelic-assisted therapy market and investors' sentiment after the FDA's decision about Lykos' MDMA ...

As Psychiatric Times reported, this decision puts on hold what could have been a landmark approval for the treatment of PTSD with MDMA, also known as midomafetamine. Despite the setback, Lykos ...